In this episode, we examine whether GLP-1 medications like semaglutide and tirzepatide can affect mood and mental health. We explore the science behind GLP-1 receptors in the brain, review clinical trial and real-world evidence, discuss three mechanisms through which these medications could influence mood including direct CNS effects, psychological adjustment to appetite changes, and blood sugar fluctuations, and provide practical guidance for patients and prescribers. Follow us on social media for updates and more content.

In this special World Health Day episode, we look at the global scale of the diabetes epidemic with over 540 million adults affected worldwide. We examine geographic disparities, the insulin access crisis in low-income countries, the staggering economic burden exceeding 960 billion dollars, evidence-based prevention strategies, and the bright spots including national programmes and technology bridging gaps in care. Follow us on social media for updates and more content.

In this episode, we break down the critical difference between diabetes distress and clinical depression, two conditions that look similar but require completely different treatment approaches. We explain what diabetes distress actually is, how it differs from clinical depression, why the distinction matters for treatment decisions, and how validated screening tools like the Diabetes Distress Scale and PHQ-9 can help get the right diagnosis. Follow us on social media for updates and more content.